Intravenous Microdose Pharmacokinetic (PK) Study With [14C]-GSK2239633

Summary

This study is a first administration to man microdose study to describe the pharmacokinetics of GSK2239633.

Timeline

Start

2010-01-21

Primary completion

2010-02-22

Completion

2010-02-22

Publications

• Background Cahn A, Hodgson S, Wilson R, Robertson J, Watson J, Beerahee M, Hughes SC, Young G, Graves R, Hall D, van Marle S, Solari R. Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study. BMC Pharmacol Toxicol. 2013 Feb 28;14:14. doi: 10.1186/2050-6511-14-14.

Drugs

Indications